Gene · 10683
Papers2,335
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 2,335
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Tarlatamab in relapsed small-cell lung cancer: a DLL3-targeted bispecific T-cell engager. | Immunotherapy | 2026 | 42077112 | PubTator, text mining | PubMed |
| Emerging therapies and translational advances in small cell lung cancer: Overcoming resistance. | Respir Investig | 2026 | 42054725 | PubTator, text mining | PubMed |
| YAP1 Defines an Emergent, Plastic Population of Relapsed SCLC. | J Thorac Oncol | 2026 | 42019833 | PubTator, text mining | PubMed |
| Comparative analysis of therapeutic target protein expression in de novo and transformed small cell lung carcinomas using paired biopsy samples. | Lung Cancer | 2026 | 42013561 | PubTator, text mining | PubMed |
| B7-H3 Gene Expression Shapes Prognosis and Therapeutic Opportunities across Patient Groups with Prostate Cancer. | Clin Cancer Res | 2026 | 42012455 | PubTator, text mining | PubMed |
| First Documented Response to Tarlatamab in a Patient With Transformed SCLC Without Actionable Gene Alteration: Case Report. | JTO Clin Res Rep | 2026 | 42006284 | PubTator, text mining | PubMed |
| Transcription Factor Subtype Governs Response and Resistance to DLL3-Directed T-Cell Engagement in Small Cell Lung Cancer. | bioRxiv | 2026 | 41993528 | PubTator, text mining | PubMed |
| Systematic review of the molecular basis for cavernous sinus invasion in somatotropinomas. | Endocr Relat Cancer | 2026 | 41989873 | PubTator, text mining | PubMed |
| Antibody-Drug Conjugates in SCLC: DLL3, B7-H3, TROP2, and Beyond. | J Thorac Oncol | 2026 | 41985715 | PubTator, text mining | PubMed |
| Precision-Engineered CD3 T-Cell Engagers for Solid Tumours: Conditional Activation, Microenvironment Modulation, and Clinical Translation. | Cancers (Basel) | 2026 | 41976311 | PubTator, text mining | PubMed |
| Advances in Delta-like Ligand 3-Targeted Diagnosis and Treatment. | Mol Pharm | 2026 | 41960617 | PubTator, text mining | PubMed |
| ESTRO-EORTC expert guideline on target delineation and radiotherapy details for stage I-III small cell lung cancer. | Radiother Oncol | 2026 | 41932500 | PubTator, text mining | PubMed |
| The Regulation and Function of Hippo/YAP Pathway in Cancer. | FASEB J | 2026 | 41924992 | PubTator, text mining | PubMed |
| Brief Report: Low Delta-Like Ligand 3 Expression and T-Cell Exhaustion Drive Resistance to Tarlatamab Combined With Anti-Programmed Cell Death Protein 1 in SCLC. | J Thorac Oncol | 2026 | 41903703 | PubTator, text mining | PubMed |
| Efficacy and safety of tarlatamab, a DLL3-targeted bispecific T-cell engager, in a patient with advanced esophageal small-cell neuroendocrine carcinoma: a case report. | Immunotherapy | 2026 | 41902878 | PubTator, text mining | PubMed |
| Receptor-Mediated Drug Delivery: Redefining Targeted Drug Conjugates in Oncology. | Pharmaceutics | 2026 | 41900872 | PubTator, text mining | PubMed |
| The role of Notch signalling and its crosstalk with oestrogen receptor signalling in breast cancer. | Cancer Metastasis Rev | 2026 | 41894035 | PubTator, text mining | PubMed |
| Four-Bar Linkage Path Generation Problems Using a New TLBO and Optimum Path Repairing Technique. | Biomimetics (Basel) | 2026 | 41892083 | PubTator, text mining | PubMed |
| Small cell lung cancer: from immunobiological mechanisms to clinical advances. | Front Immunol | 2026 | 41890737 | PubTator, text mining | PubMed |
| Delta-like ligand 3 expression in isocitrate dehydrogenase-mutant and isocitrate dehydrogenase-wildtype glioma is largely retained at recurrence, supporting its potential as a therapeutic target. | Neurooncol Adv | 2026 | 41890363 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10683/papers?page=5